Kymera Therapeutics (KYMR) Asset Writedowns and Impairment (2024 - 2025)
Kymera Therapeutics (KYMR) posted quarterly Asset Writedowns and Impairment of $45000.0 for Q4 2025, down 98.83% quarter-over-quarter from $3.9 million in Q3 2025.
Powered by 
Analysis
Kymera Therapeutics (KYMR) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Asset Writedowns and Impairment for 2 consecutive years, with $45000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $45000.0; the TTM figure through Dec 2025 stood at $3.9 million (down 20.81% YoY), while the FY2025 annual figure was $3.9 million, down 20.81% from the prior year.
- Asset Writedowns and Impairment declined to $45000.0 in Q4 2025 per KYMR's latest filing, from $3.9 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $4.9 million in Q1 2024 and bottomed at $45000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Kymera Therapeutics | 11.52 Bn | 10.83 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 45,000.00 |
| Sep 30, 2025 | 3.86 Mn |
| Mar 31, 2024 | 4.93 Mn |